{"id":"placebo-pla-mtx-db","safety":{"commonSideEffects":[{"rate":"10-25","effect":"Nausea"},{"rate":"3-10","effect":"Stomatitis"},{"rate":"10-20","effect":"Elevated liver enzymes"},{"rate":"1-5","effect":"Bone marrow suppression"},{"rate":"5-15","effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methotrexate is a folate antagonist that inhibits dihydrofolate reductase, reducing DNA synthesis and cell proliferation, particularly in rapidly dividing immune cells. In rheumatoid arthritis and other autoimmune conditions, MTX suppresses inflammatory cytokine production and T-cell activation. The placebo component serves as the control arm in this Phase 3 trial design.","oneSentence":"This is a control arm combining placebo with methotrexate (MTX), a disease-modifying antirheumatic drug that inhibits dihydrofolate reductase and reduces inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:40.175Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis (as part of control arm in Phase 3 trial)"}]},"trialDetails":[{"nctId":"NCT00095147","phase":"PHASE3","title":"Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-02","conditions":"Rheumatoid Arthritis","enrollment":431}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (PLA) + MTX, DB","genericName":"Placebo (PLA) + MTX, DB","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a control arm combining placebo with methotrexate (MTX), a disease-modifying antirheumatic drug that inhibits dihydrofolate reductase and reduces inflammation. Used for Rheumatoid arthritis (as part of control arm in Phase 3 trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}